New method to deliver treatments for dementia with Lewy bodies
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
This study is exploring a new way to deliver special treatments that can help reduce harmful proteins linked to dementia, using a friendly peptide to help get these treatments into the brain more easily, with the goal of making therapies safer and more effective for people with dementia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11230055 on NIH RePORTER |
What this research studies
This research investigates a novel approach to deliver anti-sense oligonucleotides, which are designed to target and reduce the expression of harmful proteins associated with dementia, specifically α-synuclein. The study utilizes a peptide called ApoB11 that facilitates the transport of these oligonucleotides across the blood-brain barrier, which is a significant challenge in treating neurological disorders. By administering these treatments systemically rather than through invasive methods, the research aims to improve the effectiveness and accessibility of therapies for patients with dementia and related conditions. The project will assess the pharmacokinetics and safety of this delivery method in animal models before considering human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with dementia with Lewy bodies or related neurodegenerative disorders characterized by α-synuclein accumulation.
Not a fit: Patients with neurodegenerative disorders not associated with α-synuclein or those in advanced stages of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for dementia with Lewy bodies and potentially other neurodegenerative diseases.
How similar studies have performed: While the approach of using peptides for systemic delivery of oligonucleotides is innovative, similar strategies have shown promise in other neurological conditions, indicating potential for success.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Rissman, Robert — University of Southern California
- Study coordinator: Rissman, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.